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Summary
Paget disease of bone, or “osteitis deformans,” is a bone
disorder characterized by rapid bone remodeling result-
ing in abnormal bone formation. It is the second most
common metabolic bone disease after osteoporosis, af-
fecting 3%–5% of subjects aged 140 years. Recent ev-
idence suggests that predisposition to Paget disease may
have a genetic component. Genetic linkage analysis of
families with multigenerational Paget disease shows link-
age to a region of chromosome 18q near the polymor-
phic locus D18S42. Approximately 1% of Paget patients
develop osteosarcoma, which represents an increase in
risk that is several thousandfold over that of the general
population. Osteosarcoma in Paget patients is the un-
derlying basis for a significant fraction of osteosarcomas
occurring after age 60 years. Our analysis of tumor-
specific loss of constitutional heterozygosity (LOH) in
96 sporadic osteosarcomas has identified a putative tu-
mor-suppressor locus that maps to chromosome 18q.
We have localized this tumor-suppressor locus between
D18S60 and D18S42, a region tightly linked to familial
Paget disease. Analysis of osteosarcomas from patients
with Paget disease revealed that these tumors also un-
dergo LOH in this region. These findings suggest that
the association between Paget disease and osteosarcoma
is the result of a single gene or two tightly linked genes
on chromosome 18.
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Introduction
Paget disease (MIM 167250) is a condition in which
activation of osteoclastic bone resorption and the re-
sulting stimulation of osteoblastic repair occur over a
period of years. This results in excessive new bone for-
mation in a chaotic manner, resulting in an overall de-
crease in bone strength and an increase in susceptibility
to fractures. The most frequently affected bones include
the pelvis, lumbar spine, sacrum, skull, femur, and tibia.
Although Pagetic lesions may occur in multiple sites
(polyostotic Paget disease), the disease does not spread
from bone to bone.
Paget disease is most common in Caucasians of Eur-
opean descent, but it also occurs in African Americans.
It is rare in those of Asian descent. Paget disease is sel-
dom diagnosed in people aged !40 years, but has an
estimated incidence of up to 5% in individuals aged 155
years (Ooi and Fraser 1997). It affects both sexes, but
is slightly more common in men than women.
At present, the etiology of Paget disease is uncertain.
The role of viruses in the pathogenesis of the disease has
been investigated extensively; however, no causative link
has been demonstrated between any infective agents and
Paget disease (Thomas and Shepherd 1994). Reports of
familial aggregation of Paget disease, including occur-
rence in successive generations, are common (Jacobs et
al. 1979; Brenton et al. 1980; Nassar and Gravanis
1981; Sofaer et al. 1983; Wu et al. 1991), with as many
as 40% of Paget disease patients having an affected first-
degree relative (Morales-Piga et al. 1995). The risk for
first-degree relatives of a Pagetic patient to develop Paget
disease was seven times greater than for an individual
with no affected relatives (Siris 1994), suggesting that
there may be a genetic component to predisposition for
the disease.
Familial expansile osteolysis (FEO) is a disorder sim-
ilar to Paget disease. FEO has been described in a single
extended family as an autosomal dominant bone dys-
plasia with some histological similarity to Paget disease
(Osterberg et al. 1988; Wallace et al. 1989). Unlike con-
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ventional Paget disease, the onset of the skeletal lesions
in FEO patients occurs in late adolescence to early adult-
hood. It has been proposed that Paget disease and FEO
are allelic variants of the same gene (Hughes and Barr
1996). Precedence for this is seen with Duchenne and
Becker muscular dystrophies, in which different muta-
tions in the same gene lead to different phenotypic pres-
entations (Koenig et al. 1989).
Hughes and coworkers demonstrated linkage between
FEO and a region of chromosome 18q21.1–q22 flanked
by polymorphic loci D18S51 and D18S64 (Hughes et
al. 1994; Hughes and Barr 1996). We have performed
linkage studies on a large kindred with Paget disease
(Cody et al. 1997). A total of 12 short tandem-repeat
polymorphic (STRP) loci from the region of human
chromosome 18 surrounding the FEO locus were used
to screen DNA samples from the kindred. No recom-
binants were observed between the Paget disease locus
and D18S42, giving a maximum LOD score of 3.40
(Cody et al. 1997) (this same marker showed no recom-
bination with FEO [Hughes and Barr 1996]). Thus, the
evidence strongly indicates that a locus for Paget disease
resides on 18q, which is either the same locus as FEO
or is tightly linked to the FEO locus.
One of the most serious complications of Paget disease
is osteosarcoma. By 1889, Paget had observed sarcomas
arising in 5 of his 23 patients with osteitis deformans
(Paget 1889). Various reports have placed the incidence
of osteosarcoma in Paget disease at 0.7%–5% (Freydin-
ger et al. 1963; Wick et al. 1981; Greditzer et al. 1983;
Hadjipavlou et al. 1992), with the lower frequency re-
ported in studies where both asymptomatic and symp-
tomatic cases of Paget disease were followed. Although
the incidence of osteosarcoma in Paget disease is rela-
tively low, it contributes significantly to the mortality
and morbidity of Pagetic patients (Klein and Norman
1995). Osteosarcoma related to Paget disease represents
20% of the patients with osteosarcoma who are over
the age of 40 years (Wick et al. 1981) and as many as
50% of the patients with osteosarcoma over the age of
60 years (Huvos 1986), making this complication a sig-
nificant geriatric health risk.
Evidence that the osteosarcoma is secondary to Paget
disease comes from several areas. Osteosarcoma asso-
ciated with Paget disease occurs at an age when osteo-
sarcoma is otherwise rare in the population (Sweetman
1982). In the majority of patients, there is evidence of
symptomatic Paget disease before the identification of
the tumor. Furthermore, the osteosarcoma always de-
velops in the bones that are affected by Paget disease
(Moore et al. 1991). The osteosarcoma that develops in
the Pagetic bone is characterized by the presence of a
large number of osteoclastic giant cells and atypical os-
teoblasts that resemble an exaggerated form of the re-
modeling process seen commonly in Paget disease. The
majority of Paget disease patients who develop osteo-
sarcoma have polyostotic Paget disease (Huvos et al.
1983; Schajowicz et al. 1983; Seret et al. 1987; Wu et
al. 1991), which occurs more commonly in patients with
a genetic predisposition for Paget disease (Wu et al.
1991), suggesting that there may be a link between ge-
netic predisposition to Paget disease and the occurrence
of osteosarcoma in those patients.
Consistent or frequent LOH of all or part of a chro-
mosomal arm in a tumor is a good predictor of the
presence of a tumor-suppressor gene (Hansen and Cav-
enee 1988). Yamaguchi and coworkers used LOH anal-
ysis to examine osteosarcomas for LOH on each chro-
mosomal arm (Yamaguchi et al. 1992). They found that
in their sampling of osteosarcomas, as in other tumors,
LOH for any single chromosome occurred in a detect-
able fraction of the tumors, but when they compared
the relative frequency of LOH for each individual arm
of the chromosomes separately they found that LOH
occurred more frequently on some chromosomal arms
than on others. The chromosomal arms involved most
frequently were 3q, 13q, 17p, and 18q, suggesting that
these chromosomal arms may harbor tumor-suppressor
genes important in osteosarcoma tumorigenesis. In two
cases, the tumor-suppressor loci are already known: the
retinoblastoma susceptibility gene RB1 on 13q (Friend
et al. 1986; Fung et al. 1987; Lee et al. 1987) and the
p53 gene on chromosome 17p (Masuda et al. 1987),
suggesting that this approach is a valid one for identi-
fying regions that contain tumor-suppressor genes.
Our hypothesis was that there was a gene on chro-
mosome 18q that predisposed to both osteosarcoma and
familial Paget disease. To test this, we mapped the min-
imum region of LOH for sporadic and Pagetic osteo-
sarcomas to determine whether the minimum region of
overlap included the region containing the chromosome
18q familial Paget disease locus.
Material and Methods
Patient Samples
Osteosarcoma samples were obtained from the pri-
mary or metastatic tumor sites in 96 cases. Matched
normal samples were obtained from these osteosarcoma
patients either as peripheral blood or as adjacent normal
tissue from surgical specimens. Some of these samples
were used for a previous study to map a chromosome
3q tumor-suppressor gene (Kruzelock et al. 1997). All
of the sporadic osteosarcoma patients were under 35
years of age, and none had been diagnosed with Paget
disease. Samples of osteosarcomas from patients with
Paget disease were obtained as formalin-fixed postsurg-
ical tissue samples of Pagetic bone and tumor. This re-
search was done under the approval of the Institutional
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Figure 1 Representative LOH analysis of chromosome 18q loci in osteosarcoma tumors from patients with Paget disease, using STRPs.
Matched normal (N) and tumor (T) samples were amplified by PCR by means of primers that amplify each specific polymorphic locus. Shown
are results from D18S1147, D18S60, and D18S42.
Review Board, and informed consent was obtained from
patients or their legal guardians in all cases prior to
sample acquisition.
DNA Isolation
Osteosarcoma tumors were snap frozen at 80C.
DNA was isolated from frozen tumor samples and nee-
dle biopsies by a slight modification of a procedure re-
ported elsewhere (Hansen et al. 1985). Care was taken
during the tumor DNA isolation to minimize the amount
of contaminating normal tissue. Instead of an initial hy-
potonic lysis, the frozen tumor sample was powdered in
a liquid nitrogen–cooled mortar. The frozen powder was
then mixed with a cell lysis buffer and incubated for 1
h at 42C, followed by phenol/chloroform extraction
and sodium acetate/ethanol precipitations. Matched
normal DNA was extracted either from adjacent normal
tissue as described above or from peripheral blood sam-
ples as described elsewhere (Miller et al. 1988). In either
case, the final DNA pellet was suspended in TE4 (10
mM Tris, pH 7.5, 0.1 mM EDTA).
The specimens from the Paget disease patients were
obtained as formalin-fixed samples. In these cases, DNA
was isolated as described elsewhere for paraffin-embed-
ded tumor samples (Schubert et al. 1993).
Loss of Heterozygosity Analysis
Ten polymorphic loci were used for the LOH analysis.
The simple sequence–length polymorphisms (dinucleo-
tide, trinucleotide, and tetranucleotide repeats) were
D18S487, D18S64, D18S499, D18S1148, D18S1147,
D18S60, D18S42, D18S51, D18S55, and BCL2 (listed
in proximal-to-distal order). The forward primer was
end-labeled with polynucleotide kinase and g[32P]-ATP.
The radiolabeled primer was then used in a standard
PCR reaction to amplify matched normal and tumor
DNA samples. The radiolabeled PCR amplification
products were then electrophoresed on nondenaturing
polyacrylamide gels (0.5 # TBE [0.045M Tris borate,
0.001M EDTA], 8% acrylamide) in a 38 # 50 cm se-
quencing gel apparatus. The gels were then dried and
exposed to X-ray film for 6–24 h at 70C with or
without an intensifying screen.
In some cases, we used nonradioactive analysis in our
LOH screening of tetranucleotide repeats. In these cases,
the polymorphic loci were amplified as before, except
that no radiation was added. The samples were run on
a 1.5 mm # 20 cm # 20 cm nondenaturing polyacryl-
amide gel (1 # TBE, 8% acrylamide) in a vertical gel
apparatus at 50V for 12 h and then stained with ethi-
dium bromide and photographed under UV light.
YAC Contig Construction
In order to isolate yeast artificial chromosomes (YACs)
spanning the crucial region, we first queried the CEPH/
Ge´ne´thon QUICKMAP database at the “level 7” con-
fidence index. Level 7 includes Alu PCR hybridization
and YAC fingerprinting data as well as STS-content of
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Figure 2 Summary of the data from the LOH analysis of os-
teosarcomas from Paget disease patients. Solid lines and arrows depict
the region and direction of LOH for each tumor. Note that PGOS5
shows LOH only for the region proximal to D18S42.
Figure 3 Representative LOH analysis of chromosome 18q loci in sporadic osteosarcoma tumors, using STRPs. Matched normal (N)
and tumor (T) samples were amplified by PCR by means of primers that amplify each specific polymorphic locus. Shown are results from
D18S1147, D18S60, and D18S42 that define the minimal region of LOH.
YACs for polymorphic markers described by Weissen-
bach et al. (1992). The STS markers used to identify
LOH were used to identify YACs in this region. The
chromosome 18q YACs were individually arrayed and
screened with all available chromosome 18 STSs (se-
quence information was obtained from the Genome Da-
tabase) by PCR amplification. The PCR data were con-
verted to a STS# YAC content data table and analyzed
with the SEGMAP computer program. SEGMAP is a
software package that analyzes biological physical map-
ping data and then creates contig maps from these data
(Green and Green 1991). SEGMAP generates maps
based on a set of clones and the site content information
for that set. Clone size information is used to estimate
site spacings. Each site is tested against a set of clones,
the best order of sites is determined, and a map is con-
structed that agrees with this order. In the case of data
inconsistencies, the inferred data errors in site content
data are determined. Once a YAC contig map had been
constructed, Ge´ne´thon’s genetic maps enabled us to ori-
ent the contig with respect to the centromere and
telomere.
Results
LOH Analysis of Chromosome 18 in Osteosarcoma
Samples
DNA samples from seven osteosarcomas from pa-
tients with Paget disease as well as matching Pagetic
bone tissue were analyzed for LOH with use of the
polymorphic loci D18S1147, D18S60, D18S42, and
D18S51. Six of the seven osteosarcomas from patients
with Paget disease showed LOH for the complete region
analyzed. The seventh Pagetic osteosarcoma showed
LOH for the region proximal to D18S42. Examples of
this analysis are shown in figure 1 and the data are
summarized in figure 2.
We also analyzed DNA from matched normal and
tumor tissues from 96 sporadic osteosarcoma cases with
up to 10 polymorphic loci. Of the 96 osteosarcoma tu-
mors examined, 61 (64%) showed LOH for all or part
of the region examined, while 35 (36%) showed no LOH
for the region examined.
Identification of Minimal Region of LOH
Eight tumor samples underwent mitotic recombina-
tion with breakpoints in or near the region of chro-
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Figure 4 Map of the minimal region of LOH on chromosome 18q in osteosarcoma tumors. The polymorphic loci and the physical
distances between them in kilobases, as defined by the YAC contig, are shown at top. The names of the YACs and their known sizes (in
parentheses) are shown to the left of each YAC. Blackened circles represent positive PCR amplification with primers for a locus, unblackened
circles represent negative PCR amplification with primers for a locus. Note that D18S51, D81S55, and D18S68 cannot be ordered in the contig
and are shown within a box, to represent this point. Below the YAC contig data, the solid lines and arrows depict the region and direction of
LOH for each tumor. The minimal region of LOH in the sporadic osteosarcomas as well as the region containing the familial Paget loci and
the region containing the FEO locus are shown as boxes below the arrows.
mosome 18q that contained the Paget disease/FEO loci.
Examples of the LOH analysis of this region from some
of these tumors are shown in figure 3. The regions of
LOH in these tumors were mapped to determine the
location of the minimal region of LOH common to all
nine tumor samples. Five tumor samples revealed break-
points that defined this minimal region of LOH (fig. 4).
OST 74, OST 81, and OST 86 underwent mitotic re-
combination such that the region proximal to D18S42
underwent LOH. OST 75 and OST 99 underwent mi-
totic recombination such that the region distal to
D18S60 underwent LOH. From these we were able to
conclude that the minimal region of LOH was between
D18S60 and D18S42 (fig. 4).
Discussion
To test the hypothesis that osteosarcoma, familial
Paget disease, and FEO involve either the same locus or
closely associated loci on chromosome 18q, we exam-
ined osteosarcomas from Paget disease patients for LOH
in the same chromosomal region as the familial Paget
disease and FEO loci. The discovery that the osteosar-
comas from Paget disease patients show LOH for the
same region strongly suggests that there is a genetic link
between the development of osteosarcoma and the gene
that predisposes to Paget disease and FEO. LOH has
been strongly associated with the presence of a tumor-
suppressor gene within the region of LOH (Cavenee et
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al. 1983; Hansen and Cavenee 1988; Yamaguchi et al.
1992). Interestingly, LOH for this region also occurs in
sporadic osteosarcomas, suggesting that this region may
contain a tumor-suppressor gene that is involved in both
sporadic and Pagetic osteosarcoma. Using the sporadic
osteosarcomas, we began to localize the region of LOH
to determine whether the minimal region of LOH in the
sporadic osteosarcomas coincided with the region linked
to both Paget disease and FEO. To identify the region
in which the tumor-suppressor genewas located, we used
a technique called mitotic mapping (Scrable et al. 1987),
which relies on the tendency of LOH to occur by mitotic
recombination rather than by mitotic disjunction with
loss of the entire chromosome, to sublocalize the region
of LOH on the chromosomal arm. By examining a large
number of tumors for LOH by mitotic recombination,
it is possible to localize the smallest region of LOH,
which should contain the tumor-suppressor locus, to an
area that can be physically isolated and analyzed directly
for the gene. By this analysis we were able to define a
minimal region of LOH between genetic markers
D18S60 and D18S42 on chromosome 18q. This region
does not include the 18q tumor-suppressor genes DCC
(Fearon et al. 1990) or DPC4 (Hahn et al. 1996), which
have been implicated in the development of colon cancer
and pancreatic cancer, respectively. However, it does
overlap the region in which the predisposition to both
familial Paget disease and FEO have previously been
mapped (Hughes et al. 1994; Hughes and Barr 1996;
Cody et al. 1997; Haslam et al. 1998) (fig. 4), suggesting
that there may be a genetic association between Paget
disease and osteosarcoma.
Similar associations between growth disorders or de-
velopmental disorders and cancer have also been found
to result from mutations in other tumor-suppressor
genes. Mutations in the WT1 gene have been implicated
in both Denys-Drash syndrome and Wilms tumor (Pel-
letier et al. 1991); mutations in the NF1 gene have been
linked to both von Recklinghausen neurofibromatosis
and development of neurofibrosarcomas (Hartley et al.
1988, 1990); and mutations in the RET gene have been
linked to both Hirschsprung disease and multiple en-
docrine neoplasia type 2 (Ponder 1994); whereas pa-
tients with Beckwith-Wiedemann syndrome (a hemihy-
pertrophy growth syndrome) are at increased risk of
rhabdomyosarcoma, hepatoblastoma, adrenocortical
carcinoma, and Wilms tumor (Sotelo-Avila et al. 1980;
Schneid et al. 1997). Inherited mutations in the familial
adenomatous polyposis (FAP) locus have been shown to
result in hyperproliferation of the normal colonic tissue
(Vogelstein et al. 1988). Vogelstein and coworkers dem-
onstrated that within these hyperproliferating cells a
number of somatic events occurred that eventually gave
rise to carcinoma. These additional genetic events in-
cluded the homozygous inactivation of the FAP locus
(Vogelstein et al. 1988).
An alternative model to explain the association be-
tween Paget disease and osteosarcoma would assert that,
in those patients with both Paget disease and osteosar-
coma, the association is the result of a deletion that
inactivates two adjacent genes. This would be similar to
the molecular events that give rise to the association
between aniridia and Wilms tumor. In this case, there
are two genes located within the WAGR contiguous
gene–syndrome locus on chromosome 11p (Baird et al.
1992), in which multigenic deletions inactivate both the
WT1 gene and the PAX6 gene and predispose to both
disorders. If this model is true in Paget disease, then the
mapping of the osteosarcoma tumor-suppressor gene
and the subsequent analysis of osteosarcomas from
Paget patients would reveal deletions that extend beyond
the osteosarcoma gene and into an adjacent gene, pro-
viding us with a tool to identify the Paget disease locus.
Evidence exists that at least one other familial Paget
disease locus exists in the genome. In at least one Paget
disease family, the complete chromosome 18 candidate
region has been excluded for harboring the disease-caus-
ing mutation (Haslam et al. 1998). Sporadic osteosar-
comas have been shown to undergo LOH for other chro-
mosomes as well (Yamaguchi et al. 1992), suggesting
that there may be further associations between Paget
disease predisposition and osteosarcoma tumorigenesis
that could be identified through LOH analysis.
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